Transfer of omega‐3 fatty acids across the blood–brain barrier after dietary supplementation with a docosahexaenoic acid‐rich omega‐3 fatty acid preparation in patients with Alzheimer's disease: the Omeg AD study
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Objective: Little is known about the transfer of essential fatty acids (FA s) across the human blood–brain barrier (BBB) in adulthood. In this study, we investigated whether oral supplementation with omega‐3 (n‐3) FA s would change the FA profile of the cerebrospinal fluid (CSF). Methods: A total of 33 patients (18 receiving the n‐3 FA supplement and 15 receiving placebo) were included in the study. These patients were participants in the double‐blind, placebo‐controlled randomized O meg AD study in which 204 patients with mild A lzheimer's disease (AD) received 2.3 g n‐3 FA [high in docosahexaenoic acid (DHA)] or placebo daily for 6 months. CSF FA levels were related to changes in plasma FA and to CSF biomarkers of AD and inflammation. Results: At 6 months, the n‐3 FA supplement group displayed significant increases in CSF (and plasma) eicosapentaenoic acid (EPA), DHA and total n‐3 FA levels (P < 0.01), whereas no changes were observed in the placebo group. Changes in CSF and plasma levels of EPA and n‐3 docosapentaenoic acid were strongly correlated, in contrast to those of DHA. Changes in DHA levels in CSF were inversely correlated with CSF levels of total and phosphorylated tau, and directly correlated with soluble interleukin‐1 receptor type II. Thus, the more DHA increased in CSF, the greater the change in CSF AD/inflammatory biomarkers. Conclusions: Oral supplementation with n‐3 FA s conferred changes in the n‐3 FA profile in CSF, suggesting transfer of these FA s across the BBB in adults.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION
Bligh, E. G., & Dyer, W. J. (1959) · Canadian Journal of Biochemistry and Physiology · doi:10.1139/o59-099 · Cited by 54,751
Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators
Serhan, C. N., Chiang, N., & Van Dyke, T. E. (2008) · Nature Reviews Immunology · doi:10.1038/nri2294 · Cited by 2,932
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863
Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease: A Randomized Trial
Quinn, J. F., Raman, R., Thomas, R. G., Yurko-Mauro, K., Nelson, E. B., Van Dyck, C., Galvin, J. E., Emond, J., Jack, C. R., Weiner, M., et al. (2010) · JAMA · doi:10.1001/jama.2010.1510 · Cited by 764
Freund-Levi, Y., Eriksdotter-Jönhagen, M., Cederholm, T., Basun, H., Faxén-Irving, G., Garlind, A., Vedin, I., Vessby, B., Wahlund, L.-O., & Palmblad, J. (2006) · Archives of Neurology · doi:10.1001/archneur.63.10.1402 · Cited by 751
Self-citationDocosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model
Calon, F., Lim, G. P., Yang, F., Morihara, T., Teter, B., Ubeda, O., Rostaing, P., Triller, A., Salem, N., Ashe, K. H., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.08.013 · Cited by 707
Self-citationSchaefer, E. J., Bongard, V., Beiser, A. S., Lamon-Fava, S., Robins, S. J., Au, R., Tucker, K. L., Kyle, D. J., Wilson, P. W. F., & Wolf, P. A. (2006) · Archives of Neurology · doi:10.1001/archneur.63.11.1545 · Cited by 686
Fatty acid composition of brain phospholipids in aging and in Alzheimer’s disease
Söderberg, M., Edlund, C., Kristensson, K., & Dallner, G. (1991) · Lipids · doi:10.1007/bf02536067 · Cited by 667
Cognitive decline and fatty acid composition of erythrocyte membranes—The EVA Study
Heude, B., Ducimetière, P., & Berr, C. (2003) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/77.4.803 · Cited by 363
Hashimoto, M., Tanabe, Y., Fujii, Y., Kikuta, T., Shibata, H., & Shido, O. (2005) · The Journal of Nutrition · doi:10.1093/jn/135.3.549 · Cited by 288
Cited by
Efficacy of omega-3 PUFAs in depression: A meta-analysis
Liao, Y., Xie, B., Zhang, H., He, Q., Guo, L., Subramanieapillai, M., Fan, B., Lu, C., & McIntyre, R. S. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0515-5 · Cited by 404
Docosahexaenoic Acid and Cognition throughout the Lifespan
Weiser, M., Butt, C., & Mohajeri, M. (2016) · Nutrients · doi:10.3390/nu8020099 · Cited by 400
“Cerebrospinal fluid (CSF) measures were also obtained in a small group of patients (N = 33) from the OmegAD study [264].”
BackgroundA Comprehensive Review of Chemistry, Sources and Bioavailability of Omega-3 Fatty Acids
Cholewski, M., Tomczykowa, M., & Tomczyk, M. (2018) · Nutrients · doi:10.3390/nu10111662 · Cited by 372
Involvement of Lipids in Alzheimer’s Disease Pathology and Potential Therapies
Chew, H., Solomon, V. A., & Fonteh, A. N. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00598 · Cited by 353
Omega-3 Fatty Acids and Neurodegenerative Diseases: New Evidence in Clinical Trials
Avallone, R., Vitale, G., & Bertolotti, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174256 · Cited by 218
Metadata
- Authors
- Freund Levi, Y., Vedin, I., Cederholm, T., Basun, H., Faxén Irving, G., Eriksdotter, M., Hjorth, E., Schultzberg, M., Vessby, B., Wahlund, L. ‐., Salem, N., & Palmblad, J.
- Venue
- Journal of Internal Medicine
- Publisher
- Wiley
- Published
- 2014-01-11
- Volume
- 275
- Issue
- 4
- Pages
- 428-436
- ISSN
- 0954-6820 (ISSN-L)
- 1365-2796
- OpenAlex
- W2170650084
- Cited by
- 164
- References
- 13
- FWCI
- 10.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Transfer of omega‐3 fatty acids across the blood–brain barrier after dietary supplementation with a docosahexaenoic acid‐rich omega‐3 fatty acid preparation in patients with Alzheimer's disease: the Omeg AD study. https://app.cochat.ai/papers/10.1111/joim.12166
- The paper
- Freund Levi, Y., Vedin, I., Cederholm, T., Basun, H., Faxén Irving, G., Eriksdotter, M., Hjorth, E., Schultzberg, M., Vessby, B., Wahlund, L. ‐., Salem, N., & Palmblad, J. (2014). Transfer of omega‐3 fatty acids across the blood–brain barrier after dietary supplementation with a docosahexaenoic acid‐rich omega‐3 fatty acid preparation in patients with Alzheimer's disease: the Omeg AD study. Journal of Internal Medicine. https://doi.org/10.1111/joim.12166
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.